{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:13:04Z","timestamp":1788563584347,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","award":["21OSR010"],"award-info":[{"award-number":["21OSR010"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.vph.2023.107173","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T06:05:41Z","timestamp":1681970741000},"page":"107173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The use of specific antihypertensive medication and skin cancer risk: A systematic review of the literature and meta-analysis"],"prefix":"10.1016","volume":"150","author":[{"given":"Annalena G.U.","family":"Heisel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart D.","family":"Vuurboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost G.","family":"Daams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno A.","family":"de Rie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liffert","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert-Jan H.","family":"van den Born","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik H.G.","family":"Olde Engberink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10100","key":"10.1016\/j.vph.2023.107173_bb0005","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(17)32366-8","article-title":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Gakidou","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vph.2023.107173_bb0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40256-015-0129-0","article-title":"Long-term anti-hypertensive therapy and stroke prevention: a Meta-analysis","volume":"15","author":"Mukete","year":"2015","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"19","key":"10.1016\/j.vph.2023.107173_bb0015","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1001\/jama.289.19.2534","article-title":"Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis","volume":"289","author":"Psaty","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2023.107173_bb0020","series-title":"2018 ESC\/ESH Guidelines for the Management of Arterial Hypertension the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC) and the European Society of","author":"Esh","year":"2018"},{"issue":"5","key":"10.1016\/j.vph.2023.107173_bb0025","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vph.2023.107173_bb0030","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","article-title":"Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark","volume":"78","author":"Pedersen","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.vph.2023.107173_bb0035","first-page":"473","article-title":"Use of hydrochlorothiazide and risk of skin cancer","volume":"26","author":"Pottegard","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"9","key":"10.1016\/j.vph.2023.107173_bb0040","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/sj.bjc.6604686","article-title":"Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study","volume":"99","author":"Jensen","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.vph.2023.107173_bb0045","first-page":"3","article-title":"Adverse reactions in the skin from anti-hypertensive drugs","volume":"34","author":"Thestrup-Pedersen","year":"1987","journal-title":"Dan. Med. Bull."},{"key":"10.1016\/j.vph.2023.107173_bb0050","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0378-4274(98)00237-9","article-title":"Photocarcinogenicity of drugs","volume":"102","author":"Stern","year":"1998","journal-title":"Toxicol. Lett."},{"issue":"5","key":"10.1016\/j.vph.2023.107173_bb0055","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.clindermatol.2016.05.006","article-title":"Drug-induced photosensitivity: photoallergic and phototoxic reactions","volume":"34","author":"Monteiro","year":"2016","journal-title":"Clin. Dermatol."},{"issue":"10","key":"10.1016\/j.vph.2023.107173_bb0060","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/HJH.0000000000002136","article-title":"Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer","volume":"37","author":"Kreutz","year":"2019","journal-title":"J. Hypertens."},{"issue":"15","key":"10.1016\/j.vph.2023.107173_bb0065","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2023.107173_bb0070","series-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in meta-Analyses","author":"Wells","year":"2000"},{"key":"10.1016\/j.vph.2023.107173_bb0075","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"10.1016\/j.vph.2023.107173_bb0080","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (Updated February 2022)","article-title":"Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence","author":"Sch\u00fcnemann","year":"2023"},{"issue":"7414","key":"10.1016\/j.vph.2023.107173_bb0085","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"9123","key":"10.1016\/j.vph.2023.107173_bb0090","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"Lever","year":"1998","journal-title":"Lancet (London, England)"},{"issue":"11","key":"10.1016\/j.vph.2023.107173_bb0095","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1158\/1055-9965.EPI-10-0652","article-title":"Photosensitizing medication use and risk of skin cancer","volume":"19","author":"Kaae","year":"2010","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"8","key":"10.1016\/j.vph.2023.107173_bb0100","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jdv.12921","article-title":"Use of antihypertensive drugs and risk of skin cancer","volume":"29","author":"Schmidt","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"11","key":"10.1016\/j.vph.2023.107173_bb0105","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1038\/jid.2012.227","article-title":"Predictors of basal cell carcinoma in high-risk patients in the VATTC (VA topical Tretinoin chemoprevention) trial","volume":"132","author":"Dyer","year":"2012","journal-title":"J. Investig. Dermatol."},{"issue":"6","key":"10.1016\/j.vph.2023.107173_bb0110","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/jid.2013.35","article-title":"Predictors of squamous cell carcinoma in high-risk patients in the VATTC trial","volume":"133","author":"Xiong","year":"2013","journal-title":"J. Investig. Dermatol."},{"issue":"10","key":"10.1016\/j.vph.2023.107173_bb0115","first-page":"1821","article-title":"Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened","volume":"20","author":"Friedman","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"17","key":"10.1016\/j.vph.2023.107173_bb0120","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/jnci\/djn262","article-title":"Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial","volume":"100","author":"Christian","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.vph.2023.107173_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2012.11081.x","article-title":"Known and potential new risk factors for skin cancer in European populations: a multicentre case\u2013control study","volume":"167","author":"de Vries","year":"2012","journal-title":"Br. J. Dermatol."},{"issue":"9","key":"10.1016\/j.vph.2023.107173_bb0130","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.1996.216","article-title":"Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors","volume":"73","author":"Westerdahl","year":"1996","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.vph.2023.107173_bb0135","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40264-016-0487-9","article-title":"Melanoma and non-melanoma skin Cancer associated with angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers and thiazides: a matched cohort study","volume":"40","author":"Nardone","year":"2017","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.vph.2023.107173_bb0140","first-page":"291","article-title":"Serum triglycerides and cancer risk in the metabolic syndrome and cancer (me-can) collaborative study","volume":"22","author":"Borena","year":"2011","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.vph.2023.107173_bb0145","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1056\/NEJMsb2019760","article-title":"The rapid rise in cutaneous melanoma diagnoses","volume":"384","author":"Welch","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.vph.2023.107173_bb0150","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1470-2045(21)00033-4","article-title":"Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis","volume":"22","author":"Copland","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.vph.2023.107173_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.12.003","article-title":"Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis","volume":"122","author":"Gandini","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.vph.2023.107173_bb0160","doi-asserted-by":"crossref","first-page":"247","DOI":"10.14740\/jocmr3744","article-title":"Association between the use of thiazide diuretics and the risk of skin cancers: a Meta-analysis of observational studies","volume":"11","author":"Shin","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.vph.2023.107173_bb0165","series-title":"PRAC recommendations on signals. Adopted at the 3-6 September 2018 PRAC meeting","author":"(PRAC) PRAC","year":"2018"},{"issue":"10022","key":"10.1016\/j.vph.2023.107173_bb0170","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"12","key":"10.1016\/j.vph.2023.107173_bb0175","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/HJH.0000000000000378","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials","volume":"32","author":"Thomopoulos","year":"2014","journal-title":"J. Hypertens."},{"issue":"2","key":"10.1016\/j.vph.2023.107173_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5826\/dpc.0702a01","article-title":"Epidemiological trends in skin cancer","volume":"7","author":"Apalla","year":"2017","journal-title":"Dermatol. Pract. Concept."},{"issue":"3","key":"10.1016\/j.vph.2023.107173_bb0185","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jaad.2020.08.025","article-title":"Association between hydrochlorothiazide and the risk of in-situ and invasive squamous cell skin carcinoma and basal cell carcinoma: a population-based case-control study","volume":"84","author":"Adalsteinsson","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.vph.2023.107173_bb0190","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bcpt.13463","article-title":"Risk of squamous cell carcinoma of the lip and cutaneous melanoma in older Australians using hydrochlorothiazide: a population-based case-control study","volume":"127","author":"Daniels","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"16","key":"10.1016\/j.vph.2023.107173_bb0195","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/archinternmed.2012.2754","article-title":"Antihypertensive drugs and lip cancer in non-Hispanic whites","volume":"172","author":"Friedman","year":"2012","journal-title":"Arch. Intern. Med."},{"issue":"10","key":"10.1016\/j.vph.2023.107173_bb0200","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/pds.5266","article-title":"Hydrochlorothiazide and risk of melanoma subtypes","volume":"30","author":"Habel","year":"2021","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"5","key":"10.1016\/j.vph.2023.107173_bb0205","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.canep.2009.10.005","article-title":"Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"33","author":"Koomen","year":"2009","journal-title":"Cancer Epidemiol."},{"issue":"9","key":"10.1016\/j.vph.2023.107173_bb0210","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/pds.5295","article-title":"Use of hydrochlorothiazide and risk of skin cancer in a large nested case-control study in Spain","volume":"30","author":"Leon-Munoz","year":"2021","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"7","key":"10.1016\/j.vph.2023.107173_bb0215","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/bcp.14245","article-title":"Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: a series of population-based nested case-control studies","volume":"86","author":"Morales","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.vph.2023.107173_bb0220","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2018.06.014","article-title":"Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: a nationwide case-control study","volume":"80","author":"Pedersen","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.vph.2023.107173_bb0225","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/joim.12629","article-title":"Hydrochlorothiazide use is strongly associated with risk of lip cancer","volume":"282","author":"Pottegard","year":"2017","journal-title":"J. Intern. Med."},{"issue":"8","key":"10.1016\/j.vph.2023.107173_bb0230","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamainternmed.2018.1652","article-title":"Association of hydrochlorothiazide use and risk of malignant melanoma","volume":"178","author":"Pottegard","year":"2018","journal-title":"JAMA Intern. Med."},{"issue":"11","key":"10.1016\/j.vph.2023.107173_bb0235","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41416-019-0613-4","article-title":"Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case-control study","volume":"121","author":"Potteg\u00e5rd","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"13","key":"10.1016\/j.vph.2023.107173_bb0240","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jama.279.13.1000","article-title":"Calcium Channel blockers and the risk of Cancer","volume":"279","author":"Rosenberg","year":"1998","journal-title":"JAMA."},{"key":"10.1016\/j.vph.2023.107173_bb0245","first-page":"04","article-title":"Use of hydrochlorothiazide and risk of nonmelanoma skin cancer: a pilot study in the Brazilian population","volume":"4","author":"Tiba","year":"2021","journal-title":"Int. J. Dermatol."},{"issue":"1","key":"10.1016\/j.vph.2023.107173_bb0250","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0959-8049(02)00157-0","article-title":"Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study","volume":"39","author":"Beiderbeck-Noll","year":"2003","journal-title":"Eur. J. Cancer"},{"issue":"27","key":"10.1016\/j.vph.2023.107173_bb0255","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001097","article-title":"Propranolol reduces cancer risk: a population-based cohort study","volume":"94","author":"Chang","year":"2015","journal-title":"Medicine."},{"issue":"9","key":"10.1016\/j.vph.2023.107173_bb0260","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L","article-title":"Angiotensin-converting enzyme inhibitors and the risk of cancer","volume":"92","author":"Friis","year":"2001","journal-title":"Cancer."},{"issue":"11","key":"10.1016\/j.vph.2023.107173_bb0265","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1158\/1055-9965.EPI-21-0620","article-title":"The risk of cutaneous squamous cell carcinoma among patients with type 2 diabetes receiving hydrochlorothiazide: a cohort study","volume":"30","author":"de Haan-Du","year":"2021","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"1","key":"10.1016\/j.vph.2023.107173_bb0270","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00004872-199816010-00017","article-title":"Cancer risk of hypertensive patients taking calcium antagonists","volume":"16","author":"Hole","year":"1998","journal-title":"J. Hypertens."},{"issue":"6","key":"10.1016\/j.vph.2023.107173_bb0275","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1369::AID-CNCR21>3.0.CO;2-5","article-title":"Incidence of cancer in postmyocardial infarction patients treated with short-acting nifedipine and diltiazem. Secondary Prevention Group","volume":"85","author":"Kanamasa","year":"1999","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.vph.2023.107173_bb0280","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/ced.14520","article-title":"Use of hydrochlorothiazide and risk of nonmelanoma skin cancer in Koreans: a retrospective cohort study using administrative healthcare data","volume":"46","author":"Kim","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"issue":"9","key":"10.1016\/j.vph.2023.107173_bb0285","doi-asserted-by":"crossref","first-page":"09","DOI":"10.3390\/jcm9092910","article-title":"Association between use of hydrochlorothiazide and nonmelanoma skin Cancer: common data model cohort study in Asian population","volume":"9","author":"Lee","year":"2020","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.vph.2023.107173_bb0290","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.2215\/CJN.02560220","article-title":"Association between use of hydrochlorothiazide and risk of keratinocyte cancers in kidney transplant recipients","volume":"15","author":"Letellier","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.vph.2023.107173_bb0295","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bcp.13152","article-title":"Spironolactone use and risk of incident cancers: a retrospective, matched cohort study","volume":"83","author":"Mackenzie","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.vph.2023.107173_bb0300","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1158\/1055-9965.EPI-14-0251","article-title":"Prescription diuretic use and risk of basal cell carcinoma in the nationwide U.S. radiologic technologists cohort","volume":"23","author":"McDonald","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"6","key":"10.1016\/j.vph.2023.107173_bb0305","doi-asserted-by":"crossref","first-page":"439","DOI":"10.5414\/CNP73439","article-title":"Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients","volume":"73","author":"Moscarelli","year":"2010","journal-title":"Clin. Nephrol."},{"issue":"5","key":"10.1016\/j.vph.2023.107173_bb0310","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/01.HYP.29.5.1091","article-title":"Cancer risk in users of calcium channel blockers","volume":"29","author":"Olsen","year":"1997","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"issue":"9026","key":"10.1016\/j.vph.2023.107173_bb0315","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(96)04277-8","article-title":"Calcium-channel blockade and incidence of cancer in aged populations","volume":"348","author":"Pahor","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2023.107173_bb0320","first-page":"18","article-title":"Hydrochlorothiazide use and the risk of skin cancer in patients with hypertensive disorder: a nationwide retrospective cohort study from Korea","volume":"18","author":"Park","year":"2019","journal-title":"Korean J. Intern. Med."},{"issue":"13","key":"10.1016\/j.vph.2023.107173_bb0325","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/j.ejca.2010.04.024","article-title":"High-ceiling diuretics are associated with an increased risk of basal cell carcinoma in a population-based follow-up study","volume":"46","author":"Ruiter","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.vph.2023.107173_bb0330","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00228-013-1476-x","article-title":"Exposure to phototoxic NSAIDs and quinolones is associated with an increased risk of melanoma","volume":"69","author":"Siiskonen","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.vph.2023.107173_bb0335","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/bjd.16713","article-title":"Photosensitizing antihypertensive drug use and risk of cutaneous squamous cell carcinoma","volume":"179","author":"Su","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"9281","key":"10.1016\/j.vph.2023.107173_bb0340","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(01)05704-X","article-title":"Relation between drug treatment and cancer in hypertensives in the Swedish trial in old patients with hypertension 2: a 5-year, prospective, randomised, controlled trial","volume":"358","author":"Lindholm","year":"2001","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.vph.2023.107173_bb0345","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10557-006-6312-4","article-title":"Safety of nifedipine GITS in stable angina: the ACTION trial","volume":"20","author":"Poole-Wilson","year":"2006","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"9","key":"10.1016\/j.vph.2023.107173_bb0350","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0002-9149(99)00113-7","article-title":"Verapamil and risk of cancer in patients with coronary artery disease. DAVIT study group. Danish verapamil infarction trial","volume":"83","author":"Sajadieh","year":"1999","journal-title":"Am. J. Cardiol."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189123000332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189123000332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:22:22Z","timestamp":1761528142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189123000332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":70,"alternative-id":["S1537189123000332"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2023.107173","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of specific antihypertensive medication and skin cancer risk: A systematic review of the literature and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2023.107173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107173"}}